CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.


Institute of Hematology & Blood Diseases Hospital, China

Status and phase

Phase 1


Failure of Three or More Lines of Therapy
Autologous CD19 CAR-T
Autoimmune Hemolytic Anemia


Biological: CNCT19 CAR-T cell therapy

Study type


Funder types




Details and patient eligibility


This is a Phase 1, single-arm, open-label, dose-escalation and dose-expansion study. The main purpose is to evaluate the safety and tolerability, efficacy of CNCT19 CAR T-cell therapy in patients with autoimmune hemolytic anemia after failure of three or more lines of therapy. Participants will receive CNCT19 cell infusion after preconditioning, and they will receive a 1-year follow-up.


6 estimated patients




12+ years old


No Healthy Volunteers

Inclusion criteria

  • Subject and/or subject's legal personal representative fully understand and voluntarily sign informed consent forms
  • Male or female age ≥ 12 years
  • Subjects with antibody hemolytic anemia or Evans syndrome after Failure ≥3 lines of therapy. The Failure of ≥3 lines of therapy meets all the following conditions: Hemoglobin less than 10g/dl and symptoms of anemia; Failure of first-line corticosteroid therapy; Failure of second-line rituximab therapy; Failure of any one or more of the third-line treatments (splenectomy, cyclosporine, cyclophosphamide, azathioprine, mycophenolate mofetil, fludarabine, bortezomib, etc.)
  • Female subjects of childbearing potential must have a negative Serum HCG test within 7 days before enrollment. Subjects of childbearing potential will be required to follow contraception requirements from the time of enrollment until the 1-year follow-up after cell infusion
  • Laboratory tests of adequate organ function: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN; and have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and the blood oxygen saturation in a non-oxygenated state is >93%
  • ECOG performance status ≤2
  • Subject with a life expectancy of more than 3 months

Exclusion criteria

  • History of other lymphoproliferative neoplasms
  • Secondary AIHA caused by drugs or infection
  • Platelets in subjects with Evans syndrome<30×10^9/L
  • Pregnant or breast-feeding subjects
  • Treatment with any of the following within the noted period prior to study entry: a.anti-CD20 monoclonal antibodies <12 weeks, b.sutimlimab or other marketed biologics <5 half-lives; c.plasma exchange <4 weeks; <12 weeks
  • Previously received organ or stem cell transplantation
  • History of new thrombosis or organ infarction in the past 6 months
  • Diagnosis of the active stage of the connective tissue disease
  • Had other inherited or acquired hemolytic diseases
  • Have active infections, such as sepsis, bacteremia, fungemia, uncontrolled pulmonary infection and active tuberculosis, etc.
  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg); positive hepatitis B e antibody (HBe-Ab) or hepatitis B core antibody (HBc-Ab), and the HBV-DNA copy number is above the lower limit of the measurable capacity; positive hepatitis C (HCV) antibody; positive human immunodeficiency virus (HIV) antibody; positive syphilis test
  • Received major surgery within 4 weeks before screening that was assessed by the researcher as unsuitable for enrollment
  • Have malignant tumors within 5 years before enrollment, except tumors with negligible risk of metastasis or death and curable tumors, such as adequately treated cervical carcinoma in situ, cutaneous basal cell carcinoma, etc.
  • Have any of the following cardiovascular diseases: a.Left ventricular ejection fraction (LVEF) ≤45%, b. presence of active heart disease or congestive heart failure (New York Heart Association [NYHA] Class III or IV)), c.severe arrhythmias requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia), d.QTcB interval ≥450ms for men and ≥470ms for women, e.have myocardial infarction, bypass surgery, or stent placement within the 6 months before the study, f.other heart diseases judged by the researcher to be unsuitable for enrollment
  • Have a history of live attenuated vaccines within 6 weeks before enrollment
  • Participate in other interventional clinical studies during CNCT19 CAR T-Cell therapy, and the drug has a half-life of <5. Subjects treated with active investigational drugs or intend to participate in another clinical trial or receive treatment other than that specified in the protocol throughout the study period
  • Have a history of epilepsy or other active central nervous system diseases
  • Have an allergy to the ingredients of the medicine used in this study
  • Previously received CAR-T cell therapy
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

6 participants in 1 patient group

CNCT19 CAR T-Cell Therapy
Experimental group
Participants will receive CNCT19 cell infusion after preconditioning, and they need to be closely monitored for 24 hours following CAR-T cell infusion. Participants are advised to remain in the hospital for a minimum of 14 days following cell infusion. The duration of hospitalization and observation will be determined based on the researcher's comprehensive assessment of the subject's condition.
Biological: CNCT19 CAR-T cell therapy

Trial contacts and locations



Central trial contact

Jun Shi, PhD; Jingyu Zhao, MPH

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems